Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 94 of 3101 for:    HIV Infections | NIH

The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03760458
Recruitment Status : Not yet recruiting
First Posted : November 30, 2018
Last Update Posted : July 15, 2019
Sponsor:
Collaborators:
International Maternal Pediatric Adolescent AIDS Clinical Trials Network
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
National Institute of Mental Health (NIMH)
ViiV Healthcare Ltd.
Information provided by (Responsible Party):
National Institute of Allergy and Infectious Diseases (NIAID)

Brief Summary:
The purpose of this study is to examine the pharmacokinetics, safety, and tolerability of abacavir/dolutegravir/lamivudine dispersible and immediate release tablets in HIV-1-infected children less than 12 years of age.

Condition or disease Intervention/treatment Phase
HIV Infections Drug: Abacavir (ABC)/Dolutegravir (DTG)/Lamivudine (3TC) Dispersible Tablets Drug: Abacavir (ABC)/Dolutegravir (DTG)/Lamivudine (3TC) Immediate Release Tablets (Immediate release) Phase 1 Phase 2

Detailed Description:

This study will examine the pharmacokinetics (PK), safety, and tolerability of fixed-dose combination abacavir (ABC)/dolutegravir (DTG)/lamivudine (3TC) dispersible and immediate release tablets in HIV-1-infected children less than 12 years of age.

Children will be enrolled into one of five ABC/DTG/3TC dosing groups based on their weight. The first 5-7 children within each weight-band will undergo intensive PK assessments 5-10 days after starting ABC/DTG/3TC to confirm dose selection. Children will remain on their initial dose of ABC/DTG/3TC through Week 4. After Week 4, ABC/DTG/3TC dosing will be adjusted based on PK results at the individual or weight-band level, and/or an individual child's growth and weight gain over time.

Follow-up study visits for all participants will occur at Weeks 1, 4, 12, 24, 36, and 48. Some participants may attend additional study visits at Weeks 2, 6, 8, 16, and/or 20. Study visits may include physical examination, study drug adherence and tolerability questionnaires, blood collection, and intensive PK sampling. Following the Week 48 study visit, some children may continue on the study for up to 144 weeks.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 75 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase I/II Study of the Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age
Estimated Study Start Date : October 2019
Estimated Primary Completion Date : February 28, 2021
Estimated Study Completion Date : August 31, 2023

Resource links provided by the National Library of Medicine

MedlinePlus related topics: HIV/AIDS

Arm Intervention/treatment
Experimental: Weight Band #1 (6 to less than 10 kg)
Children weighing 6 to less than 10 kg will receive 3 dispersible tablets of ABC/DTG/3TC, beginning at study entry, for at least 48 weeks and up to 144 weeks.
Drug: Abacavir (ABC)/Dolutegravir (DTG)/Lamivudine (3TC) Dispersible Tablets
Fixed-dose combination dispersible tablets containing 60 mg ABC, 5 mg DTG, and 30 mg 3TC; administered orally once daily with or without food

Experimental: Weight Band #2 (10 to less than 14 kg)
Children weighing 10 to less than 14 kg will receive 4 dispersible tablets of ABC/DTG/3TC, beginning at study entry, for at least 48 weeks and up to 144 weeks.
Drug: Abacavir (ABC)/Dolutegravir (DTG)/Lamivudine (3TC) Dispersible Tablets
Fixed-dose combination dispersible tablets containing 60 mg ABC, 5 mg DTG, and 30 mg 3TC; administered orally once daily with or without food

Experimental: Weight Band #3 (14 to less than 20 kg)
Children weighing 14 to less than 20 kg will receive 5 dispersible tablets of ABC/DTG/3TC, beginning at study entry, for at least 48 weeks and up to 144 weeks.
Drug: Abacavir (ABC)/Dolutegravir (DTG)/Lamivudine (3TC) Dispersible Tablets
Fixed-dose combination dispersible tablets containing 60 mg ABC, 5 mg DTG, and 30 mg 3TC; administered orally once daily with or without food

Experimental: Weight Band #4 (20 to less than 25 kg)
Children weighing 20 to less than 25 kg will receive 6 dispersible tablets of ABC/DTG/3TC, beginning at study entry, for at least 48 weeks and up to 144 weeks.
Drug: Abacavir (ABC)/Dolutegravir (DTG)/Lamivudine (3TC) Dispersible Tablets
Fixed-dose combination dispersible tablets containing 60 mg ABC, 5 mg DTG, and 30 mg 3TC; administered orally once daily with or without food

Experimental: Weight Band #5 (25 kg or greater)
Children weighing 25 kg or greater will receive 1 immediate release tablet of ABC/DTG/3TC, beginning at study entry, for at least 48 weeks and up to 144 weeks.
Drug: Abacavir (ABC)/Dolutegravir (DTG)/Lamivudine (3TC) Immediate Release Tablets (Immediate release)
Fixed-dose combination immediate release tablets containing 600 mg ABC, 50 mg DTG, and 300 mg 3TC; administered orally once daily with or without food
Other Name: Triumeq




Primary Outcome Measures :
  1. Geometric mean area under the plasma concentration-time curve over 24 hours at steady-state (AUC0-24h) for ABC, DTG, and 3TC [ Time Frame: Measured at Week 1 ]
    Based on analysis of intensive PK samples collected at Week 1 and compared within each weight band to the PK targets specified in the study protocol

  2. Geometric mean maximum plasma concentration (Cmax) for ABC, DTG, and 3TC [ Time Frame: Measured at Week 1 ]
    Based on analysis of intensive PK samples collected at Week 1

  3. Geometric mean concentration at 24 hours post-dose (C24h) for ABC, DTG, and 3TC [ Time Frame: Measured at Week 1 ]
    Based on analysis of intensive PK samples collected at Week 1 and compared within each weight band to the PK targets specified in the study protocol

  4. Number of participants who had adverse events [ Time Frame: Measured through Week 24 ]
    Based on the Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events (DAIDS AE Grading Table), Corrected Version 2.1, dated July 2017

  5. Number of participants who had Grade 3 or Grade 4 adverse events assessed as related to study drug [ Time Frame: Measured through Week 24 ]
    Based on DAIDS AE Grading Table, Corrected Version 2.1, dated July 2017

  6. Number of participants who had Grade 5 adverse events assessed as related to study drug [ Time Frame: Measured through Week 24 ]
    Based on DAIDS AE Grading Table, Corrected Version 2.1, dated July 2017

  7. Number of participants who had serious adverse events assessed as related to study drug [ Time Frame: Measured through Week 24 ]
    Based on DAIDS AE Grading Table, Corrected Version 2.1, dated July 2017

  8. Number of participants who had adverse events assessed as related to study drug that lead to permanent discontinuation of study drug [ Time Frame: Measured through Week 24 ]
    Based on DAIDS AE Grading Table, Corrected Version 2.1, dated July 2017


Secondary Outcome Measures :
  1. Area under the plasma concentration-time curve over 24 hours at steady-state (AUC0-24h) for ABC, DTG, and 3TC [ Time Frame: Measured through Week 48 ]
    Derived from population PK modeling with sampling

  2. Concentration at time 0 (pre-dose) (C0h) for ABC, DTG, and 3TC [ Time Frame: Measured through Week 48 ]
    Derived from population PK modeling with sampling

  3. Concentration at 24 hours post-dose (C24h) for ABC, DTG, and 3TC [ Time Frame: Measured through Week 48 ]
    Derived from population PK modeling with sampling

  4. Maximum plasma concentration (Cmax) for ABC, DTG, and 3TC [ Time Frame: Measured through Week 48 ]
    Derived from population PK modeling with sampling

  5. Time to maximum concentration (Tmax) for ABC, DTG, and 3TC [ Time Frame: Measured through Week 48 ]
    Derived from population PK modeling with sampling

  6. Apparent oral clearance (CL/F) for ABC, DTG, and 3TC [ Time Frame: Measured through Week 48 ]
    Derived from population PK modeling with sampling

  7. Half-life (t1/2) for ABC, DTG, and 3TC [ Time Frame: Measured through Week 48 ]
    Derived from population PK modeling with sampling

  8. Number of participants who had adverse events [ Time Frame: Measured through Week 48 ]
    Based on DAIDS AE Grading Table, Corrected Version 2.1, dated July 2017

  9. Number of participants who had Grade 3 or Grade 4 adverse events assessed as related to study drug [ Time Frame: Measured through Week 48 ]
    Based on DAIDS AE Grading Table, Corrected Version 2.1, dated July 2017

  10. Number of participants who had Grade 5 adverse events assessed as related to study drug [ Time Frame: Measured through Week 48 ]
    Based on DAIDS AE Grading Table, Corrected Version 2.1, dated July 2017

  11. Number of participants who had serious adverse events assessed as related to study drug [ Time Frame: Measured through Week 48 ]
    Based on DAIDS AE Grading Table, Corrected Version 2.1, dated July 2017

  12. Number of participants who had adverse events assessed as related to study drug that lead to permanent discontinuation of study drug [ Time Frame: Measured through Week 48 ]
    Based on DAIDS AE Grading Table, Corrected Version 2.1, dated July 2017

  13. Number of participants who had adverse events [ Time Frame: Measured through Week 144 ]
    Based on DAIDS AE Grading Table, Corrected Version 2.1, dated July 2017

  14. Number of participants who had Grade 3 or Grade 4 adverse events assessed as related to study drug [ Time Frame: Measured through Week 144 ]
    Based on DAIDS AE Grading Table, Corrected Version 2.1, dated July 2017

  15. Number of participants who had Grade 5 adverse events assessed as related to study drug [ Time Frame: Measured through Week 144 ]
    Based on DAIDS AE Grading Table, Corrected Version 2.1, dated July 2017

  16. Number of participants who had serious adverse events assessed as related to study drug [ Time Frame: Measured through Week 144 ]
    Based on DAIDS AE Grading Table, Corrected Version 2.1, dated July 2017

  17. Number of participants who had adverse events assessed as related to study drug that lead to permanent discontinuation of study drug [ Time Frame: Measured through Week 144 ]
    Based on DAIDS AE Grading Table, Corrected Version 2.1, dated July 2017

  18. Proportion of participants with HIV-1 RNA levels meeting virologic response criteria [ Time Frame: Measured through Week 48 ]
    Based on laboratory evaluations

  19. Proportion of participants with HIV-1 RNA levels meeting virologic response criteria [ Time Frame: Measured through Week 144 ]
    Based on laboratory evaluations

  20. Number of participant with HIV-1 RNA greater than or equal to 200 copies/mL at Weeks 4, 24, and 48 (snapshot algorithm) [ Time Frame: Measured through Week 48 ]
    Based on laboratory evaluations

  21. Number of participants with HIV-1 RNA greater than or equal to 50 copies/mL at Weeks 4, 24, and 48 (snapshot algorithm) [ Time Frame: Measured through Week 48 ]
    Based on laboratory evaluations

  22. Median changes (with IQR) in CD4+ cell count and percentage at Weeks 4, 24, and 48 [ Time Frame: Measured through Week 48 ]
    Based on laboratory evaluations

  23. Median changes (with IQR) in CD4+ cell count and percentage through Week 144 [ Time Frame: Measured through Week 144 ]
    Based on laboratory evaluations

  24. Median changes (with IQR) in total cholesterol, HDL, LDL, and triglycerides at Weeks 24 and 48 [ Time Frame: Measured through Week 48 ]
    Based on laboratory evaluations

  25. Aggregated data on parent/guardian reported adherence to study drug at Weeks 4, 24, and 48 [ Time Frame: Measured through Week 48 ]
    Based on questionnaire responses

  26. Aggregated data on parent/guardian reported tolerability (i.e., palatability and acceptability) of study drug at Weeks 4, 24, and 48 [ Time Frame: Measured through Week 48 ]
    Based on questionnaire responses

  27. ARV resistance mutations at time of virologic failure (and at entry for children with resistance identified at time of virologic failure) [ Time Frame: Measured through Week 48 ]
    Based on laboratory evaluations



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   2 Years to 12 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Less than 12 years of age at entry
  • Weight 6 kg to less than 40 kg at entry
  • Antiretroviral therapy (ART)-naïve at entry or has been taking a stable ART regimen for at least six consecutive months at entry

    • Note: For ART-naïve children, receipt of antiretroviral (ARV) prophylaxis prior to diagnosis of HIV infection is permitted. For these children, ascertainment of this criterion may be based on parent or guardian report only, but available medical records should also be reviewed in relation to this criterion.
    • Note: For ART-experienced children (on a stable ART regimen), dose and formulation changes (e.g., for growth) within the six months prior to entry are permitted. For these children, ascertainment of this criterion must be based on medical records.
  • For ART-experienced children (on a stable ART regimen), has had a suppressed HIV viral load (HIV-1 RNA less than 200 copies/mL) for at least six consecutive months prior to entry

    • Note: To fulfill this criterion, at least two documented HIV-1 RNA results less than 200 copies/mL must be available, one based on a specimen collected at least six months prior to entry and one based on a specimen collected within 30 days prior to entry.
    • Note: Any documented HIV-1 RNA result greater than or equal to 200 copies/mL based on a specimen collected within six months prior to entry is exclusionary (see exclusion criterion below).
  • At screening, has normal, Grade 1, or Grade 2 laboratory test results for all of the following, based on testing of specimens collected within 30 days prior to entry and grading per the Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events (refer to the study protocol for guidance on severity grading):

    • Hemoglobin (greater than or equal to 8.5 g/dL or greater than or equal to 5.25 mmol/L)
    • Absolute neutrophil count (greater than or equal to 600 cells/mm^3 or greater than or equal to 0.600 x 10^9 cells/L)
    • Platelet count (greater than or equal to 50,000 cells/mm^3 or greater than or equal to 50.00 x 10^9 cells/L)
    • Estimated glomerular filtration rate (eGFR; bedside Schwartz formula; greater than or equal to 60 ml/min/1.73 m^2)
    • Alanine transaminase (ALT) (less than 5.0 x ULN)
    • Aspartate aminotransferase (AST) (less than 5.0 x ULN)
    • Total bilirubin (less than 2.6 x ULN)
    • Direct bilirubin (less than or equal to ULN)
    • Note: Laboratory tests may be repeated during the screening period (i.e., within 30 days prior to entry), with the latest results used for eligibility determination.
    • Note: For treatment-experienced children on an atazanavir-containing ART regimen, Grade 3 or higher total bilirubin is permitted.
  • Confirmed HIV-1-infection based on documented testing of two samples collected at different time points:

    • Sample #1 may be tested using any of the following:

      • Two rapid antibody tests from different manufacturers or based on different principles and epitopes
      • One enzyme immunoassay OR Western Blot OR immunofluorescence assay OR chemiluminescence assay
      • One HIV DNA polymerase chain reaction (PCR)
      • One quantitative HIV RNA PCR (above the limit of detection of the assay)
      • One qualitative HIV RNA PCR
      • One HIV total nucleic acid test
    • Sample #2 may be tested using any of the following:

      • Rapid antibody test. If this option is used in combination with two rapid tests for Sample #1, at least one of the three rapid tests must be United States Food and Drug Administration (FDA)-approved, and the third rapid test must be from a third manufacturer or based on a third principle or epitope.
      • One enzyme immunoassay OR Western Blot OR immunofluorescence assay OR chemiluminescence assay
      • One HIV DNA PCR
      • One quantitative HIV RNA PCR (above the limit of detection of the assay)
      • One qualitative HIV RNA PCR
      • One HIV total nucleic acid test
    • Whole blood, plasma, or serum samples must be tested. If both samples are tested using antibody tests, at least one of the samples must be tested in a laboratory that operates according to Good Clinical Laboratory Practice guidelines and participates in an appropriate external quality assurance program. If nucleic acid testing is used, at least one test must be performed in a Clinical Laboratory Improvement Amendments (CLIA) certified (for US sites) or Virology Quality Assurance (VQA) certified (for non-US sites) laboratory. For tests performed in other settings, adequate source documentation including the date of specimen collection, date of testing, test performed, and test result must be available. FDA approved testing methods should be used when possible.
  • HLA-B*5701-negative based on documented testing at any time prior to entry

    • Note: Documented testing is required even if the potential participant has received ABC prior to study entry.
  • For females of reproductive potential (defined as having experienced menarche), not pregnant based on testing performed at screening
  • For females of reproductive potential who are engaging in sexual activity that could lead to pregnancy, willing to use two methods of contraception while receiving study drug, based on participant and parent or guardian report at entry

    • One of the two methods must be highly effective; highly effective methods include surgical sterilization (i.e., hysterectomy, bilateral oophorectomy, tubal ligation, or salpingectomy) and the following:

      • Contraceptive intrauterine device or intrauterine system
      • Subdermal contraceptive implant
      • Progestogen injections
      • Progestogen only oral contraceptive pills
      • Combined estrogen and progestogen oral contraceptive pills
      • Percutaneous contraceptive patch
      • Contraceptive vaginal ring
    • The highly effective method must be initiated prior to study entry. The second method should ideally be a barrier method. Male or female condom use is recommended with all other methods of contraception for dual protection against pregnancy and to avoid transmission of HIV and other sexually transmitted infections.
  • Based on parent or guardian report at entry, child is expected to be available for 48 weeks of follow-up
  • Parent or guardian is willing and able to provide written informed consent for child's study participation and, when applicable per local institutional review board/ethics committee (IRB/EC) policies and procedures, child is willing and able to provide written informed assent for study participation

Exclusion Criteria:

  • Less than two years of age at entry

    • Note: This age restriction reflects ViiV's currently agreed Pediatric Investigative Plan (PIP) and Pediatric Study Plan (PSP). If these plans are modified in the future, such that regulatory agreement is obtained to evaluate ABC/DTG/3TC in children less than two years of age, this restriction will be removed via a protocol Clarification Memorandum. Upon issuance of the Clarification Memorandum, study sites will be permitted to enroll children less than two years of age.
  • Documented resistance to ABC, DTG, or 3TC

    • Note: Testing to rule out resistance is not required, and the M184V resistance mutation is not exclusionary.
  • For ART-experienced children (on a stable ART regimen), documented HIV-1 RNA result greater than or equal to 200 copies/mL based on a specimen collected within six months prior to entry
  • History of any of the following as determined by the site investigator based on participant/parent/guardian report and available medical records:

    • Malignancy (ever)
    • Hypersensitivity reaction to ABC (ever)
    • Receipt of any prohibited medication (refer to the study protocol for more information) within 30 days prior to study entry
    • Receipt of systemic interferon or any chronic systemic immunosuppressant medication within 30 days prior to study entry
    • Note: Systemic corticosteroids (e.g., prednisone or equivalent up to 2 mg/kg) taken for replacement or short course therapy are permitted. Intranasal or inhaled steroid use is also permitted.
  • Has any of the following as determined by the site investigator based on participant/parent/guardian report and available medical records

    • Current clinical evidence of pancreatitis
    • Currently-active tuberculosis (TB) and/or currently receiving rifampicin-containing TB treatment
    • Currently-active AIDS-defining (WHO Clinical Stage 4) opportunistic infection
  • Has any documented or suspected clinically significant medical condition or any other condition that, in the opinion of the site investigator, would make participation in the study unsafe, complicate interpretation of study outcome data, or otherwise interfere with achieving the study objectives

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03760458


Contacts
Layout table for location contacts
Contact: Kathryn Lypen, MPH 919-544-7040 ext 11684 Klypen@fhi360.org
Contact: Emily Brown, MA 919-544-7040 ext 11123 embrown@fhi360.org

Locations
Layout table for location information
United States, California
David Geffen School of Medicine at UCLA NICHD CRS Not yet recruiting
Los Angeles, California, United States, 90095-1752
Contact: Michele F. Carter, B.S., R.N.    310-206-6369    mfcarter@mednet.ucla.edu   
United States, Colorado
Univ. of Colorado Denver NICHD CRS Not yet recruiting
Aurora, Colorado, United States, 80045
Contact: Emily Barr, C.P.N.P., C.N.M., M.S.N.    720-777-6752    emily.barr@childrenscolorado.org   
United States, Florida
Pediatric Perinatal HIV Clinical Trials Unit CRS Not yet recruiting
Miami, Florida, United States, 33136
Contact: Grace Alvarez    305-243-4447    galvarez2@miami.edu   
United States, Illinois
Rush Univ. Cook County Hosp. Chicago NICHD CRS Not yet recruiting
Chicago, Illinois, United States, 60612
Contact: Maureen McNichols, R.N., M.S.N., C.C.R.C.    312-572-4541    maureen_mcnichols@rush.edu   
Lurie Children's Hospital of Chicago (LCH) CRS Not yet recruiting
Chicago, Illinois, United States, 60614-3393
Contact: Margaret Ann Sanders, M.P.H.    312-227-8275    msanders@luriechildrens.org   
United States, Tennessee
St. Jude Children's Research Hospital CRS Not yet recruiting
Memphis, Tennessee, United States, 38105-3678
Contact: Jill Utech, M.S.N.    901-595-5059    jill.utech@stjude.org   
Sponsors and Collaborators
National Institute of Allergy and Infectious Diseases (NIAID)
International Maternal Pediatric Adolescent AIDS Clinical Trials Network
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
National Institute of Mental Health (NIMH)
ViiV Healthcare Ltd.
Investigators
Layout table for investigator information
Study Chair: Patricia Flynn, MD St. Jude Children's Research Hospital
Study Chair: Helena Rabie, MBChB, MMED, FCPaed University of Stellenbosch
Study Chair: Jennifer Kiser, PharmD University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences

Layout table for additonal information
Responsible Party: National Institute of Allergy and Infectious Diseases (NIAID)
ClinicalTrials.gov Identifier: NCT03760458     History of Changes
Other Study ID Numbers: IMPAACT 2019
38504 ( Registry Identifier: DAIDS-ES Registry Number )
First Posted: November 30, 2018    Key Record Dates
Last Update Posted: July 15, 2019
Last Verified: July 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: Individual participant data that underlie results in the publication, after deidentification.
Supporting Materials: Study Protocol
Statistical Analysis Plan (SAP)
Time Frame: Beginning 3 months following publication and available throughout period of funding of the International Maternal Pediatric Adolescent AIDS Clinical Trial (IMPAACT) Network by NIH.
Access Criteria:
  • With whom?

    • Researchers who provide a methodologically sound proposal for use of the data that is approved by the IMPAACT Network.
  • For what types of analyses?

    • To achieve aims in the proposal approved by the IMPAACT Network.
  • By what mechanism will data be made available?

    • Researchers may submit a request for access to data using the IMPAACT "Data Request" form at: https://www.impaactnetwork.org/resources/study-proposals.htm. Researchers of approved proposals will need to sign an IMPAACT Data Use Agreement before receiving the data.

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Layout table for MeSH terms
HIV Infections
Lentivirus Infections
Retroviridae Infections
RNA Virus Infections
Anti-HIV Agents
HIV Integrase Inhibitors
Virus Diseases
Sexually Transmitted Diseases, Viral
Sexually Transmitted Diseases
Immunologic Deficiency Syndromes
Immune System Diseases
Lamivudine
Abacavir
Dideoxynucleosides
Dolutegravir
Reverse Transcriptase Inhibitors
Nucleic Acid Synthesis Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Anti-Retroviral Agents
Antiviral Agents
Anti-Infective Agents
Integrase Inhibitors
Antimetabolites